Kronos Bio Inc
KRON0.880USD
+0.013+1.49%
Market hours （ET）Quotes delayed by 15 min
53.65MMarket Cap
LossP/E TTM
More Details of Kronos Bio Inc Company
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.
Company Info
Ticker SymbolKRON
Company nameKronos Bio Inc
IPO dateOct 09, 2020
CEODr. Deborah (Deb) Knobelman, Ph.D.
Number of employees10
Security typeOrdinary Share
Fiscal year-endOct 09
Address1300 S. El Camino Real
CitySAN MATEO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94402
Phone16507815200
Websitehttps://www.kronosbio.com/
Ticker SymbolKRON
IPO dateOct 09, 2020
CEODr. Deborah (Deb) Knobelman, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Margaux Bennett
Ms. Margaux Bennett
Executive Director, Business Development and Investor Relations
Executive Director, Business Development and Investor Relations
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Michael Hearne
Mr. Michael Hearne
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Margaux Bennett
Ms. Margaux Bennett
Executive Director, Business Development and Investor Relations
Executive Director, Business Development and Investor Relations
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Michael Hearne
Mr. Michael Hearne
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jun 22
Updated: Sun, Jun 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
VV Manager LLC
4.54%
The Vanguard Group, Inc.
3.15%
Partners Capital Investment Group, LLP
2.38%
Alphabet, Inc.
2.36%
Millennium Management LLC
2.34%
Other
85.24%
Shareholders
Shareholders
Proportion
VV Manager LLC
4.54%
The Vanguard Group, Inc.
3.15%
Partners Capital Investment Group, LLP
2.38%
Alphabet, Inc.
2.36%
Millennium Management LLC
2.34%
Other
85.24%
Shareholder Types
Shareholders
Proportion
Investment Advisor
8.55%
Hedge Fund
7.16%
Investment Advisor/Hedge Fund
6.09%
Individual Investor
3.65%
Venture Capital
2.49%
Research Firm
0.14%
Bank and Trust
0.04%
Family Office
0.02%
Other
71.85%
Institutional Shareholding
Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
82
2.40M
3.93%
-9.07M
2024Q4
194
35.95M
59.58%
-13.52M
2024Q3
211
35.98M
59.65%
-13.66M
2024Q2
219
35.85M
59.63%
-9.02M
2024Q1
239
34.25M
56.97%
-17.32M
2023Q4
242
37.78M
64.86%
-14.08M
2023Q3
251
39.74M
68.34%
-13.91M
2023Q2
254
41.11M
71.36%
-9.90M
2023Q1
257
41.95M
72.82%
-9.79M
2022Q4
255
43.71M
76.90%
-10.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
VV Manager LLC
--
0%
--
--
The Vanguard Group, Inc.
--
0%
--
--
Partners Capital Investment Group, LLP
--
0%
+921.15K
-100.00%
Alphabet, Inc.
--
0%
--
--
Millennium Management LLC
--
0%
-291.44K
-100.00%
Tang Capital Management, LLC
--
0%
+342.03K
-100.00%
Wildcat Capital Management, LLC
--
0%
--
--
Acadian Asset Management LLC
--
0%
-73.74K
-100.00%
Renaissance Technologies LLC
--
0%
-69.48K
-100.00%
Tanen (David M)
--
0%
--
--
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Schwab U.S. Broad Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Schwab U.S. Broad Market ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
